As of 2024-07-27, the Relative Valuation of SAGE Therapeutics Inc (SAGE) is (233.52) USD. This relative valuation is based on P/E multiples. With the latest stock price at 10.99 USD, the upside of SAGE Therapeutics Inc based on Relative Valuation is -2224.8%.
The range of the Relative Valuation is (210.96) - (206.98) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 31.8x - 47.7x | 39.8x |
| Forward P/E multiples | 30.1x - 31.2x | 30.6x |
| Fair Price | (210.96) - (206.98) | (233.52) |
| Upside | -2019.6% - -1983.4% | -2224.8% |
| Date | P/E |
| 2024-07-26 | -1.66 |
| 2024-07-25 | -1.58 |
| 2024-07-24 | -1.56 |
| 2024-07-23 | -1.97 |
| 2024-07-22 | -1.93 |
| 2024-07-19 | -1.85 |
| 2024-07-18 | -1.83 |
| 2024-07-17 | -1.83 |
| 2024-07-16 | -1.83 |
| 2024-07-15 | -1.78 |
| 2024-07-12 | -1.77 |
| 2024-07-11 | -1.77 |
| 2024-07-10 | -1.66 |
| 2024-07-09 | -1.73 |
| 2024-07-08 | -1.65 |
| 2024-07-05 | -1.62 |
| 2024-07-03 | -1.60 |
| 2024-07-02 | -1.63 |
| 2024-07-01 | -1.66 |
| 2024-06-28 | -1.64 |
| 2024-06-27 | -1.61 |
| 2024-06-26 | -1.63 |
| 2024-06-25 | -1.64 |
| 2024-06-24 | -1.74 |
| 2024-06-21 | -1.68 |
| 2024-06-20 | -1.61 |
| 2024-06-18 | -1.62 |
| 2024-06-17 | -1.70 |
| 2024-06-14 | -1.81 |
| 2024-06-13 | -1.73 |
| 2024-06-12 | -1.64 |
| 2024-06-11 | -1.60 |
| 2024-06-10 | -1.64 |
| 2024-06-07 | -1.59 |
| 2024-06-06 | -1.62 |
| 2024-06-05 | -1.65 |
| 2024-06-04 | -1.61 |
| 2024-06-03 | -1.67 |
| 2024-05-31 | -1.67 |
| 2024-05-30 | -1.73 |
| 2024-05-29 | -1.64 |
| 2024-05-28 | -1.80 |
| 2024-05-24 | -1.78 |
| 2024-05-23 | -1.71 |
| 2024-05-22 | -1.82 |
| 2024-05-21 | -1.82 |
| 2024-05-20 | -1.69 |
| 2024-05-17 | -1.76 |
| 2024-05-16 | -1.81 |
| 2024-05-15 | -1.77 |